HER2 testing in gastric cancer: a practical approach View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2012-01-06

AUTHORS

Josef Rüschoff, Wedad Hanna, Michael Bilous, Manfred Hofmann, Robert Y Osamura, Frédérique Penault-Llorca, Marc van de Vijver, Giuseppe Viale

ABSTRACT

Trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin is approved by the European Medicines Agency for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive (immunohistochemistry 3+ or immunohistochemistry 2+/fluorescence in situ hybridization-positive or immunohistochemistry 2+/silver in situ hybridization-positive) metastatic adenocarcinoma of the stomach or gastro–esophageal junction. Approvals are underway in other countries, with recent approvals granted in the United States and Japan. Experience and data from trastuzumab use in breast cancer have highlighted the importance of quality HER2 testing and scoring to ensure accurate identification of patients eligible for treatment. HER2 testing in gastric cancer differs from testing in breast cancer due to inherent differences in tumor biology; gastric cancer more frequently shows HER2 heterogeneity (focal staining) and incomplete membrane staining. Consequently, gastric cancer-specific HER2 testing protocols have been developed and standardized and it is imperative that these recommendations be adhered to. Given the predictive value of HER2 protein levels with response in the trastuzumab for GAstric cancer study (ToGA), immunohistochemistry should be the initial testing methodology and fluorescence in situ hybridization or silver in situ hybridization should be used to retest immunohistochemistry 2+ samples. Wherever possible, bright-field methodologies should be used as these are considered to be superior to fluorescent methodologies at identifying heterogeneous staining. Specific training is required before embarking on HER2 testing in gastric cancer, irrespective of the experience of HER2 testing in breast cancer. This paper provides the most up-to-date practical guidance on HER2 testing and scoring in patients with gastric and gastro–esophageal junction cancer, as agreed by a panel of expert pathologists with extensive experience of HER2 testing particularly reflecting the European Medicines Agency-approved indication. It is anticipated that these recommendations should ensure accurate and consistent HER2 testing, which will allow appropriate selection of patients eligible for treatment with trastuzumab. More... »

PAGES

637-650

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/modpathol.2011.198

DOI

http://dx.doi.org/10.1038/modpathol.2011.198

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1027273989

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22222640


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adenocarcinoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Esophageal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Esophagogastric Junction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunohistochemistry", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "In Situ Hybridization", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Practice Guidelines as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptor, ErbB-2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Silver Staining", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Stomach Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Trastuzumab", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Institute of Pathology Nordhessen, Kassel, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Targos Molecular Pathology GmbH, Kassel, Germany", 
            "Institute of Pathology Nordhessen, Kassel, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "R\u00fcschoff", 
        "givenName": "Josef", 
        "id": "sg:person.0655033461.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655033461.67"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Laboratory Medicine and Pathobiology, Anatomic Pathology, Sunnybrook Health Sciences Center, Faculty of Medicine, University of Toronto, Toronto, Canada", 
          "id": "http://www.grid.ac/institutes/grid.413104.3", 
          "name": [
            "Department of Laboratory Medicine and Pathobiology, Anatomic Pathology, Sunnybrook Health Sciences Center, Faculty of Medicine, University of Toronto, Toronto, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hanna", 
        "givenName": "Wedad", 
        "id": "sg:person.0755325725.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0755325725.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Healthscope Pathology, Norwest Private Hospital, Faculty of Medicine University of Sydney, Sydney, Australia", 
          "id": "http://www.grid.ac/institutes/grid.1013.3", 
          "name": [
            "Healthscope Pathology, Norwest Private Hospital, Faculty of Medicine University of Sydney, Sydney, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bilous", 
        "givenName": "Michael", 
        "id": "sg:person.01047412262.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01047412262.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute of Pathology Nordhessen, Kassel, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Institute of Pathology Nordhessen, Kassel, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hofmann", 
        "givenName": "Manfred", 
        "id": "sg:person.01346453747.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346453747.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "International University of Health and Welfare (IUHW), Center for Diagnostic Pathology, IUHW Mita Hospital, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.415958.4", 
          "name": [
            "International University of Health and Welfare (IUHW), Center for Diagnostic Pathology, IUHW Mita Hospital, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Osamura", 
        "givenName": "Robert Y", 
        "id": "sg:person.01356461514.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356461514.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pathology, Centre Jean Perrin and University of Auvergne, Clermont-Ferrand, France", 
          "id": "http://www.grid.ac/institutes/grid.494717.8", 
          "name": [
            "Department of Pathology, Centre Jean Perrin and University of Auvergne, Clermont-Ferrand, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Penault-Llorca", 
        "givenName": "Fr\u00e9d\u00e9rique", 
        "id": "sg:person.0643603315.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0643603315.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pathology, The Academic Medical Center (AMC), The University of Amsterdam, Amsterdam, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.7177.6", 
          "name": [
            "Department of Pathology, The Academic Medical Center (AMC), The University of Amsterdam, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "van de Vijver", 
        "givenName": "Marc", 
        "id": "sg:person.01367247364.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01367247364.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pathology and Laboratory Medicine, University of Milan and European Institute of Oncology, Milan, Italy", 
          "id": "http://www.grid.ac/institutes/grid.15667.33", 
          "name": [
            "Department of Pathology and Laboratory Medicine, University of Milan and European Institute of Oncology, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Viale", 
        "givenName": "Giuseppe", 
        "id": "sg:person.012777104037.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012777104037.00"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00292-010-1278-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044174834", 
          "https://doi.org/10.1007/s00292-010-1278-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/modpathol.3800774", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035152373", 
          "https://doi.org/10.1038/modpathol.3800774"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10620-005-9057-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006218639", 
          "https://doi.org/10.1007/s10620-005-9057-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1097/01.mp.0000052102.90815.82", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043809974", 
          "https://doi.org/10.1097/01.mp.0000052102.90815.82"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10190-009-0037-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038032671", 
          "https://doi.org/10.1007/s10190-009-0037-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00428-010-0952-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008262506", 
          "https://doi.org/10.1007/s00428-010-0952-2"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-01-06", 
    "datePublishedReg": "2012-01-06", 
    "description": "Trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin is approved by the European Medicines Agency for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive (immunohistochemistry 3+ or immunohistochemistry 2+/fluorescence in situ hybridization-positive or immunohistochemistry 2+/silver in situ hybridization-positive) metastatic adenocarcinoma of the stomach or gastro\u2013esophageal junction. Approvals are underway in other countries, with recent approvals granted in the United States and Japan. Experience and data from trastuzumab use in breast cancer have highlighted the importance of quality HER2 testing and scoring to ensure accurate identification of patients eligible for treatment. HER2 testing in gastric cancer differs from testing in breast cancer due to inherent differences in tumor biology; gastric cancer more frequently shows HER2 heterogeneity (focal staining) and incomplete membrane staining. Consequently, gastric cancer-specific HER2 testing protocols have been developed and standardized and it is imperative that these recommendations be adhered to. Given the predictive value of HER2 protein levels with response in the trastuzumab for GAstric cancer study (ToGA), immunohistochemistry should be the initial testing methodology and fluorescence in situ hybridization or silver in situ hybridization should be used to retest immunohistochemistry 2+ samples. Wherever possible, bright-field methodologies should be used as these are considered to be superior to fluorescent methodologies at identifying heterogeneous staining. Specific training is required before embarking on HER2 testing in gastric cancer, irrespective of the experience of HER2 testing in breast cancer. This paper provides the most up-to-date practical guidance on HER2 testing and scoring in patients with gastric and gastro\u2013esophageal junction cancer, as agreed by a panel of expert pathologists with extensive experience of HER2 testing particularly reflecting the European Medicines Agency-approved indication. It is anticipated that these recommendations should ensure accurate and consistent HER2 testing, which will allow appropriate selection of patients eligible for treatment with trastuzumab.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/modpathol.2011.198", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1098208", 
        "issn": [
          "0893-3952", 
          "1530-0285"
        ], 
        "name": "Modern Pathology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "25"
      }
    ], 
    "keywords": [
      "HER2 testing", 
      "European Medicines Agency", 
      "breast cancer", 
      "gastric cancer", 
      "Medicines Agency", 
      "gastro-esophageal junction cancer", 
      "human epidermal growth factor receptor 2", 
      "epidermal growth factor receptor 2", 
      "growth factor receptor 2", 
      "gastro-esophageal junction", 
      "treatment of patients", 
      "HER2 protein levels", 
      "Gastric Cancer Study", 
      "gastric cancer differs", 
      "factor receptor 2", 
      "incomplete membrane staining", 
      "trastuzumab use", 
      "metastatic adenocarcinoma", 
      "junction cancer", 
      "situ hybridization", 
      "immunohistochemistry 2", 
      "cancer differs", 
      "receptor 2", 
      "HER2 heterogeneity", 
      "predictive value", 
      "patients", 
      "recent approval", 
      "tumor biology", 
      "cancer", 
      "HER2", 
      "trastuzumab", 
      "heterogeneous staining", 
      "cancer studies", 
      "membrane staining", 
      "protein levels", 
      "expert pathologists", 
      "treatment", 
      "fluorescent methodologies", 
      "specific training", 
      "staining", 
      "testing protocol", 
      "approval", 
      "extensive experience", 
      "capecitabine", 
      "adenocarcinoma", 
      "gastric", 
      "testing", 
      "immunohistochemistry", 
      "stomach", 
      "cisplatin", 
      "pathologists", 
      "accurate identification", 
      "United States", 
      "recommendations", 
      "experience", 
      "inherent differences", 
      "indications", 
      "appropriate selection", 
      "scoring", 
      "hybridization", 
      "response", 
      "practical approach", 
      "practical guidance", 
      "levels", 
      "differences", 
      "study", 
      "protocol", 
      "training", 
      "panel", 
      "heterogeneity", 
      "guidance", 
      "junction", 
      "use", 
      "combination", 
      "differs", 
      "identification", 
      "samples", 
      "data", 
      "biology", 
      "countries", 
      "Japan", 
      "importance", 
      "agencies", 
      "values", 
      "testing methodology", 
      "fluorescence", 
      "selection", 
      "approach", 
      "state", 
      "methodology", 
      "silver", 
      "paper"
    ], 
    "name": "HER2 testing in gastric cancer: a practical approach", 
    "pagination": "637-650", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1027273989"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/modpathol.2011.198"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22222640"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/modpathol.2011.198", 
      "https://app.dimensions.ai/details/publication/pub.1027273989"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:28", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_567.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/modpathol.2011.198"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/modpathol.2011.198'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/modpathol.2011.198'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/modpathol.2011.198'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/modpathol.2011.198'


 

This table displays all metadata directly associated to this object as RDF triples.

298 TRIPLES      22 PREDICATES      137 URIs      123 LITERALS      20 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/modpathol.2011.198 schema:about N1042aad5aacf422096db97760e5ec9ba
2 N217ab32f56ad45a7bae2aa6ed964153b
3 N2278cd79efec416c84d8138f551f3db5
4 N3afed8bb385141d68bea58e2d07190d7
5 N3d7fbae7f6c74c879b7b94b12f0859ae
6 N600ed184fe8849d7b06f39c4f4a8fc3f
7 N6d896e3792ee496bb178db11f0933fda
8 N7652a0d3c41e40309eff3407e67f0777
9 N76b22f8098b94c45abb9b4e8bfea4290
10 N9370bbe23ffc4ccb9f74d4e26582328b
11 Nc0606cadcded4ef3a9abb59de23edbf6
12 Nd7bd5541c0c54edca18f3beacbc46e81
13 Nf618ab7446284692a92f0b7271205170
14 anzsrc-for:11
15 anzsrc-for:1112
16 schema:author N4e244ad41fc7412d9277f1f2d3b0987d
17 schema:citation sg:pub.10.1007/s00292-010-1278-1
18 sg:pub.10.1007/s00428-010-0952-2
19 sg:pub.10.1007/s10190-009-0037-8
20 sg:pub.10.1007/s10620-005-9057-1
21 sg:pub.10.1038/modpathol.3800774
22 sg:pub.10.1097/01.mp.0000052102.90815.82
23 schema:datePublished 2012-01-06
24 schema:datePublishedReg 2012-01-06
25 schema:description Trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin is approved by the European Medicines Agency for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive (immunohistochemistry 3+ or immunohistochemistry 2+/fluorescence in situ hybridization-positive or immunohistochemistry 2+/silver in situ hybridization-positive) metastatic adenocarcinoma of the stomach or gastro–esophageal junction. Approvals are underway in other countries, with recent approvals granted in the United States and Japan. Experience and data from trastuzumab use in breast cancer have highlighted the importance of quality HER2 testing and scoring to ensure accurate identification of patients eligible for treatment. HER2 testing in gastric cancer differs from testing in breast cancer due to inherent differences in tumor biology; gastric cancer more frequently shows HER2 heterogeneity (focal staining) and incomplete membrane staining. Consequently, gastric cancer-specific HER2 testing protocols have been developed and standardized and it is imperative that these recommendations be adhered to. Given the predictive value of HER2 protein levels with response in the trastuzumab for GAstric cancer study (ToGA), immunohistochemistry should be the initial testing methodology and fluorescence in situ hybridization or silver in situ hybridization should be used to retest immunohistochemistry 2+ samples. Wherever possible, bright-field methodologies should be used as these are considered to be superior to fluorescent methodologies at identifying heterogeneous staining. Specific training is required before embarking on HER2 testing in gastric cancer, irrespective of the experience of HER2 testing in breast cancer. This paper provides the most up-to-date practical guidance on HER2 testing and scoring in patients with gastric and gastro–esophageal junction cancer, as agreed by a panel of expert pathologists with extensive experience of HER2 testing particularly reflecting the European Medicines Agency-approved indication. It is anticipated that these recommendations should ensure accurate and consistent HER2 testing, which will allow appropriate selection of patients eligible for treatment with trastuzumab.
26 schema:genre article
27 schema:inLanguage en
28 schema:isAccessibleForFree true
29 schema:isPartOf N7b9140a7b44141db9cf04b9793d8ba67
30 Nb6b305bf12e0481d984246181d979065
31 sg:journal.1098208
32 schema:keywords European Medicines Agency
33 Gastric Cancer Study
34 HER2
35 HER2 heterogeneity
36 HER2 protein levels
37 HER2 testing
38 Japan
39 Medicines Agency
40 United States
41 accurate identification
42 adenocarcinoma
43 agencies
44 approach
45 appropriate selection
46 approval
47 biology
48 breast cancer
49 cancer
50 cancer differs
51 cancer studies
52 capecitabine
53 cisplatin
54 combination
55 countries
56 data
57 differences
58 differs
59 epidermal growth factor receptor 2
60 experience
61 expert pathologists
62 extensive experience
63 factor receptor 2
64 fluorescence
65 fluorescent methodologies
66 gastric
67 gastric cancer
68 gastric cancer differs
69 gastro-esophageal junction
70 gastro-esophageal junction cancer
71 growth factor receptor 2
72 guidance
73 heterogeneity
74 heterogeneous staining
75 human epidermal growth factor receptor 2
76 hybridization
77 identification
78 immunohistochemistry
79 immunohistochemistry 2
80 importance
81 incomplete membrane staining
82 indications
83 inherent differences
84 junction
85 junction cancer
86 levels
87 membrane staining
88 metastatic adenocarcinoma
89 methodology
90 panel
91 paper
92 pathologists
93 patients
94 practical approach
95 practical guidance
96 predictive value
97 protein levels
98 protocol
99 recent approval
100 receptor 2
101 recommendations
102 response
103 samples
104 scoring
105 selection
106 silver
107 situ hybridization
108 specific training
109 staining
110 state
111 stomach
112 study
113 testing
114 testing methodology
115 testing protocol
116 training
117 trastuzumab
118 trastuzumab use
119 treatment
120 treatment of patients
121 tumor biology
122 use
123 values
124 schema:name HER2 testing in gastric cancer: a practical approach
125 schema:pagination 637-650
126 schema:productId N0a9cb16c0db84c2092bb0ca367cc1b7e
127 N71cfe7a01e0845d1a4a424abc6396202
128 Ne6cea436edc34b908751b2ddd0a967ef
129 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027273989
130 https://doi.org/10.1038/modpathol.2011.198
131 schema:sdDatePublished 2022-05-20T07:28
132 schema:sdLicense https://scigraph.springernature.com/explorer/license/
133 schema:sdPublisher N7c93dcd96ec149b794ee0005bc88c369
134 schema:url https://doi.org/10.1038/modpathol.2011.198
135 sgo:license sg:explorer/license/
136 sgo:sdDataset articles
137 rdf:type schema:ScholarlyArticle
138 N0a3227968074415aa7a5d1d8fcf987ab rdf:first sg:person.01367247364.80
139 rdf:rest N9fe08a8f63534cd1a3a0fb16914bfc68
140 N0a9cb16c0db84c2092bb0ca367cc1b7e schema:name dimensions_id
141 schema:value pub.1027273989
142 rdf:type schema:PropertyValue
143 N1042aad5aacf422096db97760e5ec9ba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Esophageal Neoplasms
145 rdf:type schema:DefinedTerm
146 N217ab32f56ad45a7bae2aa6ed964153b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Antineoplastic Agents
148 rdf:type schema:DefinedTerm
149 N2278cd79efec416c84d8138f551f3db5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Trastuzumab
151 rdf:type schema:DefinedTerm
152 N3afed8bb385141d68bea58e2d07190d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Silver Staining
154 rdf:type schema:DefinedTerm
155 N3d7fbae7f6c74c879b7b94b12f0859ae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Stomach Neoplasms
157 rdf:type schema:DefinedTerm
158 N4e244ad41fc7412d9277f1f2d3b0987d rdf:first sg:person.0655033461.67
159 rdf:rest N927fabfb3aee406999c004bc496ce120
160 N57c7cbb4131b48298d97ad9f0c712589 rdf:first sg:person.01346453747.06
161 rdf:rest Nd27e1ffdd785413ab4acf151baca6be5
162 N600ed184fe8849d7b06f39c4f4a8fc3f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Immunohistochemistry
164 rdf:type schema:DefinedTerm
165 N6d896e3792ee496bb178db11f0933fda schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Receptor, ErbB-2
167 rdf:type schema:DefinedTerm
168 N71cfe7a01e0845d1a4a424abc6396202 schema:name pubmed_id
169 schema:value 22222640
170 rdf:type schema:PropertyValue
171 N7652a0d3c41e40309eff3407e67f0777 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Humans
173 rdf:type schema:DefinedTerm
174 N76b22f8098b94c45abb9b4e8bfea4290 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Esophagogastric Junction
176 rdf:type schema:DefinedTerm
177 N7b9140a7b44141db9cf04b9793d8ba67 schema:volumeNumber 25
178 rdf:type schema:PublicationVolume
179 N7c93dcd96ec149b794ee0005bc88c369 schema:name Springer Nature - SN SciGraph project
180 rdf:type schema:Organization
181 N927fabfb3aee406999c004bc496ce120 rdf:first sg:person.0755325725.02
182 rdf:rest Nd650f51ba0a943fba1fc66917ff9bd27
183 N9370bbe23ffc4ccb9f74d4e26582328b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Adenocarcinoma
185 rdf:type schema:DefinedTerm
186 N9fe08a8f63534cd1a3a0fb16914bfc68 rdf:first sg:person.012777104037.00
187 rdf:rest rdf:nil
188 Nb6b305bf12e0481d984246181d979065 schema:issueNumber 5
189 rdf:type schema:PublicationIssue
190 Nc0606cadcded4ef3a9abb59de23edbf6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Antibodies, Monoclonal, Humanized
192 rdf:type schema:DefinedTerm
193 Nc9f248726d184171b0a1e959c69cf06b rdf:first sg:person.0643603315.57
194 rdf:rest N0a3227968074415aa7a5d1d8fcf987ab
195 Nd27e1ffdd785413ab4acf151baca6be5 rdf:first sg:person.01356461514.40
196 rdf:rest Nc9f248726d184171b0a1e959c69cf06b
197 Nd650f51ba0a943fba1fc66917ff9bd27 rdf:first sg:person.01047412262.17
198 rdf:rest N57c7cbb4131b48298d97ad9f0c712589
199 Nd7bd5541c0c54edca18f3beacbc46e81 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Practice Guidelines as Topic
201 rdf:type schema:DefinedTerm
202 Ne6cea436edc34b908751b2ddd0a967ef schema:name doi
203 schema:value 10.1038/modpathol.2011.198
204 rdf:type schema:PropertyValue
205 Nf618ab7446284692a92f0b7271205170 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
206 schema:name In Situ Hybridization
207 rdf:type schema:DefinedTerm
208 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
209 schema:name Medical and Health Sciences
210 rdf:type schema:DefinedTerm
211 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
212 schema:name Oncology and Carcinogenesis
213 rdf:type schema:DefinedTerm
214 sg:journal.1098208 schema:issn 0893-3952
215 1530-0285
216 schema:name Modern Pathology
217 schema:publisher Springer Nature
218 rdf:type schema:Periodical
219 sg:person.01047412262.17 schema:affiliation grid-institutes:grid.1013.3
220 schema:familyName Bilous
221 schema:givenName Michael
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01047412262.17
223 rdf:type schema:Person
224 sg:person.012777104037.00 schema:affiliation grid-institutes:grid.15667.33
225 schema:familyName Viale
226 schema:givenName Giuseppe
227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012777104037.00
228 rdf:type schema:Person
229 sg:person.01346453747.06 schema:affiliation grid-institutes:None
230 schema:familyName Hofmann
231 schema:givenName Manfred
232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346453747.06
233 rdf:type schema:Person
234 sg:person.01356461514.40 schema:affiliation grid-institutes:grid.415958.4
235 schema:familyName Osamura
236 schema:givenName Robert Y
237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356461514.40
238 rdf:type schema:Person
239 sg:person.01367247364.80 schema:affiliation grid-institutes:grid.7177.6
240 schema:familyName van de Vijver
241 schema:givenName Marc
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01367247364.80
243 rdf:type schema:Person
244 sg:person.0643603315.57 schema:affiliation grid-institutes:grid.494717.8
245 schema:familyName Penault-Llorca
246 schema:givenName Frédérique
247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0643603315.57
248 rdf:type schema:Person
249 sg:person.0655033461.67 schema:affiliation grid-institutes:None
250 schema:familyName Rüschoff
251 schema:givenName Josef
252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655033461.67
253 rdf:type schema:Person
254 sg:person.0755325725.02 schema:affiliation grid-institutes:grid.413104.3
255 schema:familyName Hanna
256 schema:givenName Wedad
257 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0755325725.02
258 rdf:type schema:Person
259 sg:pub.10.1007/s00292-010-1278-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044174834
260 https://doi.org/10.1007/s00292-010-1278-1
261 rdf:type schema:CreativeWork
262 sg:pub.10.1007/s00428-010-0952-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008262506
263 https://doi.org/10.1007/s00428-010-0952-2
264 rdf:type schema:CreativeWork
265 sg:pub.10.1007/s10190-009-0037-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038032671
266 https://doi.org/10.1007/s10190-009-0037-8
267 rdf:type schema:CreativeWork
268 sg:pub.10.1007/s10620-005-9057-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006218639
269 https://doi.org/10.1007/s10620-005-9057-1
270 rdf:type schema:CreativeWork
271 sg:pub.10.1038/modpathol.3800774 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035152373
272 https://doi.org/10.1038/modpathol.3800774
273 rdf:type schema:CreativeWork
274 sg:pub.10.1097/01.mp.0000052102.90815.82 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043809974
275 https://doi.org/10.1097/01.mp.0000052102.90815.82
276 rdf:type schema:CreativeWork
277 grid-institutes:None schema:alternateName Institute of Pathology Nordhessen, Kassel, Germany
278 schema:name Institute of Pathology Nordhessen, Kassel, Germany
279 Targos Molecular Pathology GmbH, Kassel, Germany
280 rdf:type schema:Organization
281 grid-institutes:grid.1013.3 schema:alternateName Healthscope Pathology, Norwest Private Hospital, Faculty of Medicine University of Sydney, Sydney, Australia
282 schema:name Healthscope Pathology, Norwest Private Hospital, Faculty of Medicine University of Sydney, Sydney, Australia
283 rdf:type schema:Organization
284 grid-institutes:grid.15667.33 schema:alternateName Department of Pathology and Laboratory Medicine, University of Milan and European Institute of Oncology, Milan, Italy
285 schema:name Department of Pathology and Laboratory Medicine, University of Milan and European Institute of Oncology, Milan, Italy
286 rdf:type schema:Organization
287 grid-institutes:grid.413104.3 schema:alternateName Department of Laboratory Medicine and Pathobiology, Anatomic Pathology, Sunnybrook Health Sciences Center, Faculty of Medicine, University of Toronto, Toronto, Canada
288 schema:name Department of Laboratory Medicine and Pathobiology, Anatomic Pathology, Sunnybrook Health Sciences Center, Faculty of Medicine, University of Toronto, Toronto, Canada
289 rdf:type schema:Organization
290 grid-institutes:grid.415958.4 schema:alternateName International University of Health and Welfare (IUHW), Center for Diagnostic Pathology, IUHW Mita Hospital, Tokyo, Japan
291 schema:name International University of Health and Welfare (IUHW), Center for Diagnostic Pathology, IUHW Mita Hospital, Tokyo, Japan
292 rdf:type schema:Organization
293 grid-institutes:grid.494717.8 schema:alternateName Department of Pathology, Centre Jean Perrin and University of Auvergne, Clermont-Ferrand, France
294 schema:name Department of Pathology, Centre Jean Perrin and University of Auvergne, Clermont-Ferrand, France
295 rdf:type schema:Organization
296 grid-institutes:grid.7177.6 schema:alternateName Department of Pathology, The Academic Medical Center (AMC), The University of Amsterdam, Amsterdam, The Netherlands
297 schema:name Department of Pathology, The Academic Medical Center (AMC), The University of Amsterdam, Amsterdam, The Netherlands
298 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...